康诺亚(02162.HK) 公布,国家药监局已于近日批准司普奇拜单抗(抗IL-4Rα单克隆抗体,商品名:康悦达,研发代号:CM310)治疗慢性鼻窦炎伴鼻息肉的新适应症上市申请(sNDA)。
本次获批是基于一项多中心、随机、双盲、安慰剂对照的III期临床研究,主要用于确证司普奇拜单抗注射液在治疗慢性鼻窦炎伴鼻息肉患者中的有效性及安全性。研究结果显示该项III期临床试验数据结果积极。(jl/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-23 16:25。)
康诺亚(02162.HK) 公布,国家药监局已于近日批准司普奇拜单抗(抗IL-4Rα单克隆抗体,商品名:康悦达,研发代号:CM310)治疗慢性鼻窦炎伴鼻息肉的新适应症上市申请(sNDA)。
本次获批是基于一项多中心、随机、双盲、安慰剂对照的III期临床研究,主要用于确证司普奇拜单抗注射液在治疗慢性鼻窦炎伴鼻息肉患者中的有效性及安全性。研究结果显示该项III期临床试验数据结果积极。(jl/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-23 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.